Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
48.69
+1.19 (+2.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
28
29
Next >
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
October 01, 2023
These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.
Via
InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
October 01, 2023
These three top mid-cap stocks could be poised for a long-tailed growth spurt.
Via
The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
September 29, 2023
These stocks have what it takes to grow in leaps and bounds.
Via
The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
September 28, 2023
The FDA is within three months of making a decision on the first-ever CRISPR-based drug.
Via
Investor's Business Daily
Exposures
Product Safety
2 Bargain Growth Stocks to Buy Hand Over Fist
September 28, 2023
Both stocks have declined in recent times.
Via
The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
September 12, 2023
You can get in early on these potential winners.
Via
The Motley Fool
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
September 27, 2023
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.
Via
InvestorPlace
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
September 27, 2023
Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
September 24, 2023
These two high-tech stocks could dramatically outperform the broader market in the years ahead.
Via
The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
September 21, 2023
I favor holding onto these players for the long term to truly benefit from their earnings potential.
Via
The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
September 20, 2023
These two biotechs have a lot in common, but one is much better capitalized.
Via
The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
September 19, 2023
The company hasn't performed well in the past five years, but things could change.
Via
The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
2 Top Trends to Invest $500 In Right Now
September 18, 2023
Early investors in these trends may reap the rewards over time.
Via
The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
September 17, 2023
Catalysts on the horizon could drive gains in these top stocks.
Via
The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
September 16, 2023
The returns are impressive, but will they continue to be so?
Via
The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
September 15, 2023
They're both liable to grow by a lot, but one of them is a safer bet in the near term.
Via
The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
3 Top Healthcare Stocks Defying the Bear Market
September 15, 2023
Revenue at all three companies improved last quarter, and their share prices have followed suit.
Via
The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
September 14, 2023
Investors may look for growth stocks ahead of the next bull market.
Via
The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
September 12, 2023
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.
Via
InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
September 12, 2023
These companies are innovators, something that can prove highly lucrative.
Via
The Motley Fool
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down
September 07, 2023
With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock.
Via
InvestorPlace
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
September 06, 2023
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.
Via
The Motley Fool
With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?
September 05, 2023
Big news could come in December and in March.
Via
The Motley Fool
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.